ReviewEmerging microbes & infections2016
Updates on the risk factors for latent tuberculosis reactivation and their managements.
Review in Emerging microbes & infections, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 4 syntheses or guidelines pooled it, 293 citations in OpenAlex.
- Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2024Pooled it
- Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2021Pooled it
- Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies.International journal of chronic obstructive pulmonary disease · 2019Pooled it
- The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Pooled it
- Multimethod analysis of adherence to preventive treatment for tuberculosis: a pragmatic randomized clinical trial.BMC infectious diseases · 2026Trial
- The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response AgainstFrontiers in immunology · 2018Trial
- LTBI Prevalence and Risk Factors in Field Practice Areas of a Tertiary Care Hospital, Jodhpur, Rajasthan.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026Article
- Interferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study.Scientific reports · 2026Article
- Latent Tuberculosis Activation Due to Short-Term Glucocorticoid Use in Acute Systemic Lupus Erythematosus.Cureus · 2026Article
- Effect of Variability on Interferon-Gamma Release Assay Performance: A Quantitative Analysis.Annals of laboratory medicine · 2026Article
- Schistosoma mansoni co-infection in tuberculosis patients with or without human immunodeficiency virus and factors associated with treatment outcomes: a prospective cohort study.BMC infectious diseases · 2026Article
- Multidisciplinary management of thyroid eye disease (TED) in patients with latent tuberculosis or chronic hepatitis B.Thyroid research · 2026Article
- Machine Learning Models for Predicting Latent Tuberculosis Infection Risk in Close Contacts of Patients with Pulmonary Tuberculosis - Henan Province, China, 2024.China CDC weekly · 2026Article
- Modelling tuberculosis transmission dynamics in Malaysia.Frontiers in public health · 2026Article
- Tuberculosis incidence in patients treated with secukinumab - a real-world study in Brazil.Advances in rheumatology (London, England) · 2025Observational
- The inflammasome adaptor pycard is essential for immunity against Mycobacterium marinum infection in adult zebrafish.Disease models & mechanisms · 2025Article
- The Role of Type I Interferons in Tuberculosis and in Tuberculosis-Risk-Associated Comorbidities.Infectious disease reports · 2025Review
- Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion.PLoS neglected tropical diseases · 2025Article
- Tuberculosis risk in patients with Crohn's disease on biologics: a retrospective analysis of the Japanese Medical Claims Database.Intestinal research · 2025Article
- Advancement in diagnostic approaches for latent tuberculosis: distinguishing recent from remote infections.One health outlook · 2025Review
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The preventive treatment of latent tuberculosis infection (LTBI) is of great importance for the elimination and control of tuberculosis (TB) worldwide, but existing screening methods for LTBI are still limited in predicting the onset of TB. Previous studies have found that some high-risk factors (including human immunodeficiency virus (HIV), organ transplantation, silicosis, tumor necrosis factor-alpha blockers, close contacts and kidney dialysis) contribute to a significantly increased TB reactivation rate. This article reviews each risk factor's association with TB and approaches to address those factors. Five regimens are currently recommended by the World Health Organization, and no regimen has shown superiority over others. In recent years, studies have gradually narrowed down to the preventive treatment of LTBI for high-risk target groups, such as silicosis patients, organ-transplantation recipients and HIV-infected patients. This review discusses regimens for each target group and compares the efficacy of different regimens. For HIV patients and transplant recipients, isoniazid monotherapy is effective in treating LTBI, but for others, little evidence is available at present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.